Ghent University Academic Bibliography

Advanced

Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL

Graham Pineo, Jay Lin, Lee Stern, Tarun Subrahmanian and Lieven Annemans UGent (2011) CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 17(2). p.150-157
abstract
The efficacy and safety of low-molecular-weight heparins (LMWHs) versus unfractionated heparin (UFH) has been demonstrated for the prevention of venous thromboembolism (VTE) after acute ischemic stroke. Few data exist regarding the economic impact of LMWHs versus UFH in this population. A decision-analytic model was constructed using clinical information from the Prevention of VTE after Acute Ischemic stroke with LMWH Enoxaparin (PREVAIL) study, and drug costs and mean Centers for Medicare & Medicaid Services event costs. When considering the total cost of events and drugs, enoxaparin was associated with cost-savings of $895 per patient compared with UFH ($2018 vs $2913). Findings were retained within the univariate and multivariate analyses. From a payer perspective, enoxaparin was cost-effective compared with UFH in patients with acute ischemic stroke. The difference was driven by the lower clinical event rates with enoxaparin. Use of enoxaparin may help to reduce the clinical and economic burden of VTE.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
thrombosis prophylaxis, anticoagulants, deep venous thrombosis, venous thromboembolism, DEEP-VEIN THROMBOSIS, LOW-MOLECULAR-WEIGHT, ILL MEDICAL PATIENTS, VENOUS THROMBOEMBOLISM, UNFRACTIONATED HEPARIN, PREVENTION, PROPHYLAXIS, THROMBOPROPHYLAXIS, RISK, COSTS
journal title
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
Clin. Appl. Thromb.-Hemost.
volume
17
issue
2
pages
150 - 157
Web of Science type
Article
Web of Science id
000288463500005
JCR category
PERIPHERAL VASCULAR DISEASE
JCR impact factor
1.332 (2011)
JCR rank
51/67 (2011)
JCR quartile
4 (2011)
ISSN
1076-0296
DOI
10.1177/1076029610389026
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2014504
handle
http://hdl.handle.net/1854/LU-2014504
date created
2012-02-01 11:44:07
date last changed
2015-06-17 09:56:00
@article{2014504,
  abstract     = {The efficacy and safety of low-molecular-weight heparins (LMWHs) versus unfractionated heparin (UFH) has been demonstrated for the prevention of venous thromboembolism (VTE) after acute ischemic stroke. Few data exist regarding the economic impact of LMWHs versus UFH in this population. A decision-analytic model was constructed using clinical information from the Prevention of VTE after Acute Ischemic stroke with LMWH Enoxaparin (PREVAIL) study, and drug costs and mean Centers for Medicare \& Medicaid Services event costs. When considering the total cost of events and drugs, enoxaparin was associated with cost-savings of \$895 per patient compared with UFH (\$2018 vs \$2913). Findings were retained within the univariate and multivariate analyses. From a payer perspective, enoxaparin was cost-effective compared with UFH in patients with acute ischemic stroke. The difference was driven by the lower clinical event rates with enoxaparin. Use of enoxaparin may help to reduce the clinical and economic burden of VTE.},
  author       = {Pineo, Graham and Lin, Jay and Stern, Lee and Subrahmanian, Tarun and Annemans, Lieven},
  issn         = {1076-0296},
  journal      = {CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS},
  keyword      = {thrombosis prophylaxis,anticoagulants,deep venous thrombosis,venous thromboembolism,DEEP-VEIN THROMBOSIS,LOW-MOLECULAR-WEIGHT,ILL MEDICAL PATIENTS,VENOUS THROMBOEMBOLISM,UNFRACTIONATED HEPARIN,PREVENTION,PROPHYLAXIS,THROMBOPROPHYLAXIS,RISK,COSTS},
  language     = {eng},
  number       = {2},
  pages        = {150--157},
  title        = {Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL},
  url          = {http://dx.doi.org/10.1177/1076029610389026},
  volume       = {17},
  year         = {2011},
}

Chicago
Pineo, Graham, Jay Lin, Lee Stern, Tarun Subrahmanian, and Lieven Annemans. 2011. “Economic Impact of Enoxaparin After Acute Ischemic Stroke Based on PREVAIL.” Clinical and Applied Thrombosis-hemostasis 17 (2): 150–157.
APA
Pineo, G., Lin, J., Stern, L., Subrahmanian, T., & Annemans, L. (2011). Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 17(2), 150–157.
Vancouver
1.
Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS. 2011;17(2):150–7.
MLA
Pineo, Graham, Jay Lin, Lee Stern, et al. “Economic Impact of Enoxaparin After Acute Ischemic Stroke Based on PREVAIL.” CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS 17.2 (2011): 150–157. Print.